Aurobindo Pharma Limited — Q2 FY24
Aurobindo Pharma delivered a strong Q2 FY24 with revenue of INR 7,219 crore (+25.8% YoY), EBITDA of INR 1,403 crore (+67.7% YoY), and PAT of INR 752 crore (+83.6% YoY).
bullish
high
✓ Verified against BSE filing
Indian management teams deliver on roughly 12% of specific earnings-call promises. A low score does not indicate dishonesty — it reflects how aspirational forward guidance typically is.
Q1 FY24
FY24 EBITDA margin target of 18%+ (ex-Revlimid)
Management targets 18%+ EBITDA margin for FY24, excluding Revlimid contribution, supported by operating leverage and export benefit normalization.
Missed
Current-quarter commentary contains related risk or weakness, so the promise appears not to have been delivered yet.
heuristic_v1